Peritoneal Metastases of Colorectal Origin Treated with Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy: The Efficiency of Mitomycin C.
Fiche publication
Date publication
juillet 2022
Journal
Annals of surgical oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROHR Serge, Dr ROMAIN Benoit, Pr BRIGAND Cécile
Tous les auteurs :
Delhorme JB, Sauvinet G, Séverac F, Diab S, Liu D, Rohr S, Romain B, Brigand C
Lien Pubmed
Résumé
Survival of patients affected by colorectal cancer peritoneal metastases (CRC-PM) can be improved with combined complete cytoreductive surgery (CCRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Two chemotherapeutic agents are mainly used: mitomycin C (MMC) and oxaliplatin. A recent prospective randomized clinical trial showed that oxaliplatin-based HIPEC does not improve survival compared with CCRS alone. The purpose of our study was to compare the survival effectiveness of MMC versus oxaliplatin-based HIPEC using a homogeneous surgical technique and drug protocol.
Référence
Ann Surg Oncol. 2022 07 26;: